# **European Cystic Fibrosis Society**

## **Annual Report**

1. january 2009 - 31. december 2009

# **Contents**

	<u>Page</u>
Statement and Report	
Independent Auditors' Report	2
Financial Statements	
Accounting Policies	3
Profit and loss account 1 January - 31 December	4
Balance Sheet at 31 December	5
Specifications	7

### **Independent Auditors' Report**

#### To the European Cystic Fibrosis Society

We have audited the Annual Report of European Cystic Fibrosis Society for the financial year 1 January - 31 December 2009, which comprises a summary of significant accounting policies, the income statement, balance sheet, and specifications. The Annual Report has been prepared in accordance with the Danish Financial Statements Act.

#### The Supervisory and Executive Boards' Responsibility for the Annual Report

The Supervisory and Executive Boards are responsible for the preparation and fair presentation of this Annual Report in accordance with the Danish Financial Statements Act. This responsibility includes: designing, implementing and maintaining internal control relevant to the preparation and fair presentation of an Annual Report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

#### Auditor's Responsibility and Basis of Opinion

Our responsibility is to express an opinion on this Annual Report based on our audit. We conducted our audit in accordance with Danish Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance whether the Annual Report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Annual Report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Annual Report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the Annual Report in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors and Board of Executives, as well as evaluating the overall presentation of the Annual Report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Our audit has not resulted in any qualification.

#### Opinion

In our opinion, the Annual Report gives a true and fair view of the financial position at 31 December 2009 and of the results of the financial year 1 January - 31 December 2009 in accordance with the Danish Financial Statements Act.

Viborg, 26. may 2010

#### **Dansk Revision Viborg**

Registreret revisionsaktieselskab

Jens Ole Klemmensen
Registered Public Accountant

# **Accounting Policies**

The Annual Report for EUROPEAN CYSTIC FIBROSIS SOCIETY for the financial year 2009 has been presented in accordance with the provisions of the Danish Financial Statements Act applying to reporting class B.

The accounting policies are unchanged from last year.

#### Profit and loss account

#### Conference expenses

Expenses paid concerning conferences in 2009 are registered in the profit and loss account for the year 2009, and expenses concerning conferences in 2010 are registered as prepaid expenses.

#### Administrative expenses

Administrative expenses include office expenses etc.

#### Financial items

Financial items comprise interest, realised and unrealised exchange rate adjustments, realised capital gains and profit/loss on securities.

#### **Balance Sheet**

#### Tangible fixed assets

Operating equipment are not registered as an asset. In 2009 investments for DKK 31.875 is registered as administration costs.

#### Receivables

Receivables are recognised in the balance sheet at amortised cost, usually corresponding to nominal value less provisions for bad debts.

#### Investments

Investments are recognised in the balance sheet under liquid at cost price.

#### Other debt

Other debts are recognised at cost at the time of contracting the debt.

#### **Translation policies**

Transactions in foreign currencies are translated at the exchange rates at the balance sheet date. Receivables, payables and other items in foreign currencies that have not been settled at the balance sheet date are translated at the exchange rates at the balance sheet date.

Realised and unrealised exchange adjustments are recognised in financial income and expenses in the income statement.

### **Profit and loss account 1/1 - 31/12 2009**

		DKK	EUR
	Membership fees	428.276	57.487
	Donations (not earmarked)	186,250	25.000
	Bonations (not carmaned)	100.200	20.000
	INCOME TOTAL	614.526	82.487
1	Personnel costs	-1.038.141	-139.348
2	Other administration Costs	-281.097	-37.730
3	Travel costs	-82.979	-11.139
	GENERAL OPERATING COSTS, TOTAL	-1.402.217	-188.217
4	Journal	131.768	17.687
5	Promotion and information	-9.495	-1.274
6	CTN (Clinical Trials Network)	-522.581	-70.145
7	Various activities	-27.661	-3.713
	ACTIVITIES COSTS TOTAL	-427.969	-57.445
8	Consensus conferences/Carrier Screening	285.472	38.318
9	Consensus conferences/AHP research in CF	-16.270	-2.184
10	32ND ECFC, Brest 2009	2.870.114	385.250
11	Basic science conference, Tavira 2009	-162.613	-21.827
	CONFERENCES (ALL) TOTAL	2.976.703	399.557
	RESULT BEFORE INTERESTS	1.761.043	236.382
12	Interests income	204.622	27.466
	RESULT FOR THE YEAR	1.965.665	263.848

# Balance Sheet at 31. december 2009

	DKK	EUR
ASSETS		
CURRENT ASSETS		
Current account CDU	-11.491	-1.542
Outstanding amounts	397.011	53.29
Interest receivable	60.000	8.054
Deposit, Valencia 2010	187.830	25.21
OUTSTANDINGS TOTAL	633.350	85.01
Cash foreign currencies	506	6
Nordea DKK 212442	3.137.819	421.18
Nordea DKK 154953	520.376	69.84
Nordea DKK 542577	1.359.725	182.51
Nordea EURO 155851	4.210.722	565.19
Nordea Investments	3.506.969	470.73
LIQUIED TOTAL	12.736.117	1.709.54
CURRENT ASSETTS TOTAL	13.369.467	1.794.56
ASSETTS TOTAL	13.369.467	1.794.56

### Balance Sheet at 31. december 2009

		DKK	EUR
	LIABILITIES		
	Miscellaneous expenses	1.356.125	182.031
	Prepaid, membership fee	143.045	19.201
	Prepaid, sponsorships etc	22.350	3.000
	Prepaid, Basic Science Registration	7.440	999
13	Prepaid, Registry	737.993	99.059
14	Prepaid, EurocareCF Projects	160.521	21.546
	Accounting	19.300	2.591
	A-skat	29.473	3.956
	AM contribution	6.069	815
	ATP	1.620	217
	Pension	7.056	947
	Holiday allowance	107.000	14.362
	SHORT-TERMS DEBTS TOTAL	2.597.992	348.724
	Net Capital 2008	8.805.810	1.181.988
	Result for the year 2009	1.965.665	263.848
	NET CAPITAL TOTAL	10.771.475	1.445.836
	LIABILITES TOTAL	13.369.467	1.794.560

### **Specifications**

	Specifications		
		DKK	EUR
	Salary and pension	-1.023.328	-137.359
	Travel Allowance	-3.678	-137.339
	ATP, employers costs	-6.480	-870
	AER, apprentice scheme	-1.905	-256
	Barsels Tax	-1.298	-174
	Prolon fees	-1.452	-195
1	PERSONNEL COSTS	-1.038.141	-139.348
	Rental/Costs of facilities	-39.029	-5.239
	Insurance	-8.370	-1.123
	Postage, freight	-6.028	-809
	Telephone, fax, email, WEB	-39.873	-5.352
	Office equipment	-44.402	-5.960
	Office supplies	-6.364	-854
	ADP supplies, hardware	-19.925	-2.674
	ADP supplies, software-support	-25.210	-3.384
	Bank fees/membership payments	-24.380	-3.272
	PBS fees/membership payments	-1.197	-161
	Bank fees	-4.940 -16.800	-663 -2.255
	Auditing Cass stolen	-22.035	-2.255 -2.958
	Miscellane expenses	-22.035 -175	-2.936
	Foreign Exchange Diff.	-22.369	-3.003
2	OTHER ADMINISTRATION COSTS TOTAL	-281.097	-37.730
	Travel/Secretarial CDU	-22.661	-3.042
	Travel/meet./Board members	-52.802	-7.088
	Travel/meet./other	-7.516	-1.009
3	TRAVEL COSTS TOTAL	-82.979	-11.139
	lournal/Incomo	482.227	64.728
	Journal/Income Journal./Costs, Subscription	-350.459	-47.041
	·		,
	JOURNAL TOTAL	131.768	17.687
	Prom+info/other items	-9.495	-1.274
5	PROMOTION AND INFORMATION TOTAL	-9.495	-1.274
			-

# **Specifications**

	Specifications	DKK	EUR
		DIKK	LUIN
	Clinical Trials Network	-11.715	-1.572
	Clinical Trials income	167.359	22.464
	CTN Coord Centre Leuven	-678.225	-91.037
6	CTN TOTAL	-522.581	-70.145
	Project sponsorship	-18.640	-2.502
	Membership fees	-6.703	-900
	Insurance, travel Miscl. expenses, incl. present	-159 -2.159	-21 -290
7	VARIOUS ACTIVITIES TOTAL	-27.661	-3.713
	Cons/Sponsorships	420.865	56.492
	Cons/Venue Costs	-83.998	-11.275
	Cons/Travel & Transportation	-41.937	-5.629
	Cons/PCO costs	-9.458	-1.270
8	CONSENSUS CONFERENCES/CARRIER SCREENING	285.472	38.318
	Cons/Sponsorships	176.078	23.635
	Cons/Venue Costs	-99.978	-13.420
	Cons/Travel & Transportation	-80.450	-10.799
	Cons/PCO costs	-11.920	-1.600
9	CONSENSUS CONFERENCES/AHP RESEARCH IN CF	-16.270	-2.184
	On an acception / Economical	400.040	40.000
	Sponsorship/Earmarked Income, Other	126.640 3.272.356	16.999 439.242
	Planning-Travel-Meeting	-34.936	-4.689
	Scientific Committee Travel	-25.163	-3.378
	Abstract Handling	-50.892	-6.831
	Speaker fees	-293.484	-39.394
	Awards & Rossi Medal	-39.623	-5.319
	ECFS Expenses and refund	-84.784	-11.380
10	32ND ECFC, BREST 2009	2.870.114	385.250

### **Specifications**

	Specifications			
		DKK	EUR	
	0	407.000	47.070	
	Sponsorship	127.236	17.079	
	Travel	-6.758	-907	
	Conference Venue costs	-439.205	-58.954	
	Speakers	-154.826	-20.782	
	Registration Fees	322.115	43.237	
	Awards	-11.175	-1.500	
11	BASIC SCIENCE CONFERENCE, TAVIRA 2009	-162.613	-21.827	
	Interests, income from bank savings	113.292	15.207	
	Interests, income from investments	91.330	12.259	
12	INTERESTS, INCOME TOTAL	204.622	27.466	
	Sponsorship, IERFC	521.480	69.997	
	Expenses, IERFC	-251.165	-33.713	
	Sponsorship, Chiesi	521.480	69.997	
	Expenses, Chiesi	-53.802	-7.222	
13	PREPAID, REGISTRY	737.993	99.059	
	EuroCareCF Funds	192.925	25.896	
	WP1 Meeting	-32.404	-4.350	
14	PREPAID, EUROCARECF PROJECTS	160.521	21.546	